
    
      Dose escalation study to test the safety (Phase I), pharmacology and preliminary clinical
      activity (Phase II) of a Novel histone deacetylase (HDAC) inhibitor, LBH589, in the treatment
      of the following GVHD presentations: Classic, Late-onset acute GVHD, Recurrent acute GVHD,
      Overlap syndrome.
    
  